Is modified FOLFIRINOX a standard regimen for 2nd line chemotherapy for pancreatic cancer after gemcitabine plus nab-paclitaxel failure?—insights from the MPACA-3 trial
@article{DMR8216, author = {Toshihiko Matsumoto and Shogo Yamamura and Hiroki Nagai and Hironaga Satake and Hisateru Yasui}, title = {Is modified FOLFIRINOX a standard regimen for 2nd line chemotherapy for pancreatic cancer after gemcitabine plus nab-paclitaxel failure?—insights from the MPACA-3 trial}, journal = {Digestive Medicine Research}, volume = {5}, number = {0}, year = {2022}, keywords = {}, abstract = {}, issn = {2617-1627}, url = {https://dmr.amegroups.org/article/view/8216} }